Moleculin Biotech (MBRX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$7.6M

Net income growth (year over year)

+57.13%

Net margin

—

Return on equity

−1471.05%

EPS (trailing twelve months)

$14.59

Book value per share

$1.63

P/E (trailing twelve months)

—

Price to book

0.75

Debt to assets

45.05%

Payout ratio

—

Dividend yield

—

Company profile

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

• How do I buy stock in Moleculin Biotech (MBRX)?

  MBRX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.